Can Amlodipine Cause Pleural Effusion?
Yes, amlodipine can cause pleural effusion, though this is an uncommon adverse effect not prominently listed in the FDA drug label, and when evaluating a patient with pleural effusion on amlodipine, you must systematically rule out other causes before attributing it to the medication.
Evidence from FDA Drug Label
The official FDA labeling for amlodipine does not list pleural effusion as a recognized adverse effect 1. The most common adverse reactions in clinical trials involving over 11,000 patients were:
- Peripheral edema (dose-related: 1.8% at 2.5mg to 10.8% at 10mg, particularly in women at 14.6%)
- Dizziness, flushing, and palpitations
- Dyspnea (reported in <1% of patients in the respiratory system category)
Notably, in the PRAISE-2 heart failure study, there were more reports of pulmonary edema with amlodipine compared to placebo 1, suggesting potential for fluid accumulation in the lungs, though this was in the context of advanced heart failure patients.
Clinical Guidelines on Drug-Induced Pleural Effusion
The 2023 British Thoracic Society guideline explicitly states that drug history should always be recorded as numerous medications cause exudative pleural effusions 2. The guideline recommends using the Pneumotox app for comprehensive drug-related pleural disease data and notes that tyrosine kinase inhibitors are now the most common drug culprits, indicating the evolving landscape of drug-induced pleural effusions.
Case Report Evidence
A 2022 veterinary case report documented amlodipine-induced pleural effusion in a dog receiving high-dose amlodipine for severe systemic hypertension 3. The effusion was a pure transudate, resolved within 24 hours of dose reduction, and occurred after ruling out hypoalbuminemia and thromboembolism. While this is animal data, it demonstrates biological plausibility.
A 2024 case report of amlodipine overdose (430mg) in a human documented non-cardiogenic pulmonary edema as a manifestation of toxicity 4, further supporting that high doses can cause pulmonary fluid accumulation through mechanisms beyond cardiac dysfunction.
Clinical Approach When Evaluating Pleural Effusion in a Patient on Amlodipine
Step 1: Assess for More Common Causes First
Following the 2024 ERS and 2023 BTS guidelines 5, 2:
Cardiac causes:
- Measure NT-proBNP (≥1500 pg/mL suggests cardiac origin)
- Perform echocardiography looking for systolic/diastolic heart failure, valve abnormalities
- Assess for interstitial syndrome on thoracic ultrasound
- Check for elevated central venous pressure via IVC assessment
Other priority diagnoses to exclude:
- Malignancy (look for pleural nodularity, thickening on ultrasound)
- Tuberculosis
- Pulmonary embolism
- Lymphoma
- IgG4 disease
Step 2: Consider Amlodipine as Causative
If the following criteria are met:
- Other causes systematically ruled out
- Temporal relationship between amlodipine initiation/dose increase and effusion onset
- Effusion is likely exudative (though the veterinary case showed transudate)
- Patient may be on higher doses or have other risk factors for fluid retention
Step 3: Diagnostic Trial
Consider reducing or discontinuing amlodipine and monitoring for effusion resolution over days to weeks. If effusion resolves, this supports the diagnosis.
Key Clinical Caveats
- Amlodipine-induced pleural effusion is rare and not well-documented in standard human clinical trials
- Peripheral edema is far more common (up to 14.6% in women) and may coexist
- The mechanism likely involves increased capillary permeability and fluid extravasation, similar to peripheral edema
- Do not assume amlodipine is the cause without systematic evaluation per guidelines 2—missing malignancy, heart failure, or PE would have serious mortality implications
- Women and patients on higher doses (10mg) are at higher risk for fluid-related adverse effects
Practical Recommendation
When encountering pleural effusion in a patient on amlodipine: perform thoracic ultrasound, measure NT-proBNP, obtain echocardiography, and review the complete drug history using resources like Pneumotox 2. Only after excluding life-threatening causes should you consider a trial of amlodipine dose reduction or discontinuation with close monitoring for effusion resolution.